Traders should monitor Dr. Reddy's for potential revenue upside from the 180-day exclusivity period, but note that this is a single-strength launch in a competitive generic space. Watch for any subsequent first-to-file exclusivity on other strengths or additional generic oncology launches that could compound the impact.
Price Chart
Executive Summary
Dr. Reddy's announced the first-to-market launch of Bosutinib Tablets 400mg (generic Bosulif) in the U.S., a tyrosine kinase inhibitor for oncology. The product was a first-to-file and qualifies for 180-day generic exclusivity for this strength. The Bosulif brand had U.S. sales of ~$253.8M over the latest 12 months ended April 2026. This is a positive, event-driven catalyst that expands Dr. Reddy's oncology portfolio, limited to a single strength and a finite exclusivity window.
Key Facts
- First-to-market launch of Bosutinib Tablets 400mg, generic equivalent of Bosulif, in the United States on June 13, 2026.
- Product is a first-to-file, eligible for 180-day generic exclusivity for this strength.
- Brand Bosulif (400mg) had U.S. sales of approximately $253.8 million for the latest 12 months ended April 2026.
- Dr. Reddy's holds exclusive marketing rights; MSN Laboratories is the development and manufacturing partner.
- Launch expands Dr. Reddy's oncology portfolio in the U.S. market.
Financial Impact
U.S. brand sales of ~$253.8M (LTM) for the 400mg strength, but generic revenue will be a fraction of that and subject to competition after 180-day exclusivity.
Risk Factors
- Generic pricing erosion and competition from other manufacturers after the 180-day exclusivity period
- Product launch delays or supply disruptions from partner MSN Laboratories
- Litigation risk from branded manufacturer (Wyeth/Pfizer) regarding patent validity or exclusivity scope
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000418 |
| Document: 0001575872-26-000418-index.html | 0001575872-26-000418 |
| Document: 0001575872-26-000418.txt | 0001575872-26-000418 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $11.91 $11.55 | ▼ −3.02% | ▼ −2.56% | $12.25 (+2.85%) |
Sep 10, 2026 22d ago | 6-K | $11.71 $11.90 | ▲ +1.62% | ▲ +0.77% | $12.25 (+4.61%) |
Sep 10, 2026 22d ago | 6-K | $11.71 $11.90 | ▲ +1.62% | ▲ +0.77% | $12.25 (+4.61%) |
Aug 26, 2026 5w ago | 6-K | $12.22 $12.16 | ▼ −0.49% | ▼ −1.15% | $12.25 (+0.25%) |
Aug 17, 2026 6w ago | 6-K | $12.11 $12.15 | ▲ +0.33% | ▲ +1.01% | $12.25 (+1.16%) |
Aug 13, 2026 7w ago | 6-K | $12.42 $12.27 | ▼ −1.21% | ▼ −1.01% | $12.25 (−1.37%) |
Aug 10, 2026 7w ago | 6-K | $12.15 $12.45 | ▲ +2.47% | ▲ +2.79% | $12.25 (+0.82%) |
Aug 3, 2026 8w ago | 6-K | $12.07 $12.10 | ▲ +0.25% | ▼ −1.55% | $12.25 (+1.49%) |
Jul 29, 2026 9w ago | 6-K | $11.76 $11.83 | ▲ +0.60% | ▼ −1.08% | $12.25 (+4.17%) |
Jul 23, 2026 10w ago | 6-K | $11.80 $11.79 | ▼ −0.08% | ▼ −0.19% | $12.25 (+3.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access